Literature DB >> 26980213

Association of cytomegalovirus infection with hypertension risk: a meta-analysis.

Jing Hui1, Yuan-Yuan Qu1,2, Na Tang1, Yong-Min Liu1, Hua Zhong1, La-Mei Wang3, Qian Feng1, Zhen Li1, Fang He4.   

Abstract

BACKGROUND: Information regarding association between cytomegalovirus (CMV) infection and essential hypertension (EH) risk is not consistent across studies. Therefore, we conducted a meta-analysis to investigate the association in detail.
METHODS: We comprehensively searched the published literature from the PubMed and Embase databases for any study analyzing the association between CMV and EH risk. A random-effects model was used to calculate the pooled odds ratio (OR) with 95 % confidence interval (CI).
RESULTS: Three studies involving 9657 patients were included in the meta-analysis, and the results showed a significantly increased risk of EH in patients with CMV infection. Overall, 79.3 % of the hypertension patients were CMV-positive, which was significantly higher than the percentage for controls (OR = 1.39, 95 % CI = 0.95-2.05, P = 0.017). There was significant heterogeneity among the studies included (I(2) = 70.5 %). The funnel plot and Egger's test also indicated no publication bias.
CONCLUSIONS: The results showed a significant association between CMV and EH, which indicates that CMV infection is a possible cause of EH.

Entities:  

Keywords:  Cytomegalovirus; Essential hypertension; Meta-analysis

Mesh:

Year:  2016        PMID: 26980213      PMCID: PMC5010589          DOI: 10.1007/s00508-016-0977-x

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


Background

Essential hypertension (EH) is the most common form of hypertension [1] and is a major risk factor for cardiovascular, cerebrovascular, and renal diseases. Hypertension is a multifactorial disease [2], and its development involves both genetic and environmental factors; however, the specific mechanism and risk factors remain unclear. As a member of the human Herpesviridae family, cytomegalovirus (CMV) contains double-stranded DNA [3] and establishes a latent infection that can persist for the lifetime of the host. Despite being nearly ubiquitous in the population [4], overt human CMV disease in adults is typically restricted to immunocompromised individuals [5-7]. In healthy individuals, both primary infection and the reactivation of latent virus rarely cause any significant clinical symptoms owing to the robust immune response of the host. CMV infection is associated with various chronic inflammatory diseases, including cardiovascular diseases (CVDs) [8] such as myocarditis, atherosclerosis, and coronary artery disease [9-11]. Hypertension is an important cause of CVDs, and recent studies [12-18] have shown that patients with a CMV infection have an increased risk of EH; however, the association between CMV and EH remains unclear, and thus the effect of CMV infection on blood pressure is controversial. Therefore, we performed the present meta-analysis to more comprehensively investigate the association between CMV and EH.

Materials and methods

Literature search and selection

We comprehensively searched the PubMed and Embase databases up to July 2015. The search key words used included “EH or hypertension”, “blood pressure”, and “CMV”. Relevant articles in the reference lists of the published literature were also searched manually for other potential studies.

Inclusion and exclusion criteria

Studies were included in the meta-analysis if they met the following criteria (1) case-control study, (2) investigated the positive rate of CMV in hypertension patients and controls, (3) hypertension is defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) of 140 or 90 mmHg, respectively, (4) not an animal study. Studies were excluded if insufficient details were reported to be able to perform the meta-analysis.

Data extraction

Two authors (JH and Y-YQ) extracted the data independently. In cases where any data were lacking from an article, the authors of selected studies were contacted directly for the missing data. The two reviewers came to an agreement before the final analysis. The following information was extracted from each study: first author’s name, year of publication, country, ethnicity, CMV detection method, patient characteristics, the sample sizes of cases and controls, and the relationship between CMV and EH.

Statistical analysis

We performed statistical analyses using Stata statistical software ver.12.0. (Stata Corporation, College Station, TX, USA). Meta-analysis was conducted by combining odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) for the association between the CMV-positive rate of hypertension patients and controls. Heterogeneity across all selected studies was evaluated using the Q-test and the I2 statistic (range 0–100 %) [19] and was judged to be significant when P < 0.1 or I2 > 50 %, respectively. We select the random-effects model in the analysis if significant heterogeneity was observed across studies; otherwise, the fixed-effects model was used. Sensitivity analysis was performed with the random-effects model to evaluate the stability of the crude results by removing one study at a time. The Begg’s funnel plot and Egger’s linear regression test were performed to determine the level of potential publication bias [20, 21]. A P-value lower than 0.05 was considered statistically significant.

Results

Characteristics of studies included

A total of three articles [12, 13, 16] were included in the meta-analysis, comprising 2347 cases and 7310 controls. All of the studies used enzyme-linked immunosorbent assay (ELISA), and one study [12] used a combination of ELISA and polymerase chain reaction (PCR). ELISA was used to determine the titer of anti-HCMV IgG antibodies, and quantitative PCR was used to test the HCMV DNA copy number. The flow diagram for the search process is shown in Fig. 1. The characteristics of the selected studies are given in Table 1.
Fig. 1

Flow diagram of the study selection process

Table 1

Details of studies included in the meta-analysis

ReferenceYearEthnicity/CountryCMV detection N Male (%)Cases (n = 2347)Controls (n = 7310)Result
CMV+CMV-CMV+CMV-
[12]2014Han/ChinaELISA, PCR80042.84334928830CMV antibody titers associated with blood pressure and hypertension
Kazakh/China80042.04521531122CMV seropositivity associated with hypertension in males
[16]2013IranELISA175449.2442171193102Pathogen burden not associated with hypertension
[13]2012USAELISA630347.353440529022462CMV seropositivity associated with hypertension in women

ELSA enzyme-linked immunosorbent assay, PCR polymerase chain reaction, CMV cytomegalovirus

Flow diagram of the study selection process Details of studies included in the meta-analysis ELSA enzyme-linked immunosorbent assay, PCR polymerase chain reaction, CMV cytomegalovirus

Meta-analysis results

We pooled data from all studies included and analyzed the association between CMV and EH risk. A total of 79.3 % of the hypertension patients were CMV-positive compared with 64.2 % of the controls. The pooled OR was 1.39 (95 % CI = 0.95–2.05, P = 0.017). We used a random-effects model, given the significant heterogeneity (I2 = 70.5 %) observed across studies. The overall result of the meta-analysis is shown as a forest plot in Fig. 2.
Fig. 2

Forest plot of the cytomegalovirus (CMV)-positive rate in hypertension patients versus controls. OR odds ratio, CI confidence interval

Forest plot of the cytomegalovirus (CMV)-positive rate in hypertension patients versus controls. OR odds ratio, CI confidence interval

Sensitivity analysis

Sensitivity analysis was conducted to evaluate the stability of the crude results. The results showed that no single study substantially affected the stability of the crude results, given the lack of change in the ORs after exclusion of one study at a time (Fig. 3). Therefore, the results of this meta-analysis were deemed to be reliable.
Fig. 3

Sensitivity analysis

Sensitivity analysis

Publication bias

Begg’s funnel plot and Egger’s test were used to evaluate the potential publication bias. Although Begg’s funnel plot was not symmetrical, the Egger’s linear regression test indicated that there was no significant publication bias (Fig. 4; P = 0.361).
Fig. 4

Funnel plot to evaluate potential publication bias in studies evaluating the association between cytomegalovirus (CMV) and essential hypertension risk

Funnel plot to evaluate potential publication bias in studies evaluating the association between cytomegalovirus (CMV) and essential hypertension risk

Discussion

CMV infection has been reported to be associated with hypertension [12-18]. Regardless of the approach used, both negative and positive associations have been reported; therefore, the role of CMV in hypertension remains controversial. Discrepancies between different studies might be due to differences in sample size, age, ethnicity, region, dietary habits, climate, lifestyles, and immune responses to CMV infection, among other factors. Besides, the seroprevalence is considerably high in China [12] to other evaluated studies’ countries, we believe that low socioeconomic status is also a factor affecting the seropositivity [22] in most Asian countries that are still developing countries, especially China. When a human is first infected, CMV replicates in many different cells. The virus can remain a latent state for the life of its host. In most immunocompetent individuals, the CMV infection is mild or even asymptomatic. Viruses modulate the intracellular environment so that it is optimized to support the viral life cycle. With heightened stress or immunosuppression, however, latent CMV can be reactivated reinitiating productive replication and causing clinical problems, especially in immunosuppressed or immunocompromised patients. Moreover, CMV infection has been shown to be associated with the increased arterial blood pressure via stimulation with renin and cytokine production in mice [23]. Recently, several previous studies have investigated the role of CMV seropositivity as a risk factor for hypertension. In a Chinese cohort, Tang et al. [12]. showed that CMV seropositivity was significantly associated with hypertension after adjustment for age in Kazakh males but not in females. However, in another study cohort [13], CMV seropositivity was associated with hypertension in females before, but not after, adjusting for age. By contrast, another study in a Chinese cohort [14] showed that plasma CMV deoxyribonucleic acid (DNA) copy number was associated with hypertension. Few studies have examined the CMV antibody titer as a risk factor for hypertension. One study [15] showed that CMV antibody titers were independent determinants for SBP and DBP elevation in young males but not in females. By contrast, Tang et al. [12] demonstrated that, in both Han Chinese males and females, CMV antibody titers were significantly independently associated with hypertension. However, Vahdat et al. [16] failed to show any significant association between viral infections and hypertension in patients from Iran. In this meta-analysis, we selected three studies [12, 13, 16], including 2347 cases and 7310 controls; all the studies included were population-based cross-sectional studies. We constructed a forest plot to obtain the pooled OR and demonstrated that patients with CMV infection showed a higher risk of EH. Although the mechanism underlying how CMV might cause EH remains unclear, there are several possible explanations for this link. First, oxidative stress and inflammation might play a role [24, 25]. Reactive oxygen species (ROS) have been shown to be generated in response to CMV infection [26] and are also directly involved in vasoconstriction [27-30] and vascular inflammation [31]. CMV infection can induce an inflammatory reaction through modulation of inflammatory mediators that evoke vasoconstriction, such as cytokines, chemokines, and adhesion molecules [32-34]. Second, CMV might influence hypertension via regulation of the renin-angiotensin system. CMV infection has been shown to induce the generation of angiotensin II (AngII) [25], which reacts with endothelial nitric oxide synthase to promote vasoconstriction; this may also enhance the production of ROS [35, 36]. An in vivo experimental study showed that CMV infection increased arterial pressure and further stimulated the expression of renin and increased AngII levels in the blood and arterial tissues [23], which can lead to arterial constriction. Third, the immune response triggered by CMV infection could itself lead to hypertension. Indeed, suppression of the immune system has been shown to depress blood pressure in both experimental animals and humans [37]. Finally, genomic-related changes could be involved in the mechanism. In particular, DNA methylation of gene promoter region [38-40] and the corresponding changes in mRNA expression [14] are also involved in regulating blood pressure. The studies included there are not enough, so we need more prospective studies to prove the link. The results of the present meta-analysis suggest that CMV may be a contributing factor to the development of EH. However, there are limitations to the meta-analysis that should be acknowledged. First, although the pooled sample size of the studies included was sufficiently large to carry out the meta-analysis, the number of studies included is not as large as we had hoped for in order to perform a comprehensive analysis. In particular, this limited our ability to conduct a subgroup analysis to explore the influence of sample size, ethnicity, age, or other factors and to explore the nature of the observed heterogeneity. Therefore, these findings should be interpreted with caution, and more studies are needed to confirm the results of this meta-analysis.

Conclusions

The results showed a significant association between CMV and EH, which indicates that CMV infection is a possible cause of EH.

Source of support

This project was supported by the Joint Funds of the National Natural Science Foundation of China (No.U1403123) and the Ministry of Major Science & Technology of Shihezi University (Nos.gxjs2013-zdgg04, gxjs2013-zdgg04-1, gxjs2013-zdgg04-2, gxjs2013-zdgg04-3, and gxjs2013-zdgg04-4) and the Xinjiang Graduate Student Research Innovation Project (No. XJGRI2015054). No conflict of interest exists in this study.
  39 in total

Review 1.  Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs).

Authors:  D M Juilfs; S Soderling; F Burns; J A Beavo
Journal:  Rev Physiol Biochem Pharmacol       Date:  1999       Impact factor: 5.545

2.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 3.  NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.

Authors:  M Grilli; J J Chiu; M J Lenardo
Journal:  Int Rev Cytol       Date:  1993

4.  Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis.

Authors:  S P Adler; J K Hur; J B Wang; G W Vetrovec
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

Review 5.  Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling.

Authors:  K Irani
Journal:  Circ Res       Date:  2000-08-04       Impact factor: 17.367

6.  Role of superoxide anions in the mediation of endothelium-dependent contractions.

Authors:  F Cosentino; J C Sill; Z S Katusić
Journal:  Hypertension       Date:  1994-02       Impact factor: 10.190

7.  Seroprevalence and risk factors of human cytomegalovirus infection in the eastern Chinese population.

Authors:  Ping Zhao; Daoxin Ma; Fuzhong Xue; Chunyan Ji; Shukang Wang; Xiaomei Zhang; Yabin Zhou; Xiuping Yu
Journal:  Arch Virol       Date:  2009-03-05       Impact factor: 2.574

8.  The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study.

Authors:  Agha W Haider; Peter W F Wilson; Martin G Larson; Jane C Evans; Eric L Michelson; Philip A Wolf; Christopher J O'Donnell; Daniel Levy
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

9.  Expressional and epigenetic alterations of placental matrix metalloproteinase 9 in preeclampsia.

Authors:  Zhuoqun Wang; Shuang Lu; Chunmei Liu; Baojian Zhao; Kaiyan Pei; Ling Tian; Xu Ma
Journal:  Gynecol Endocrinol       Date:  2010-02       Impact factor: 2.260

10.  A genome-wide methylation study on essential hypertension in young African American males.

Authors:  Xiaoling Wang; Bonita Falkner; Haidong Zhu; Huidong Shi; Shaoyong Su; Xiaojing Xu; Ashok Kumar Sharma; Yanbin Dong; Frank Treiber; Bernard Gutin; Gregory Harshfield; Harold Snieder
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

View more
  13 in total

Review 1.  Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases.

Authors:  Undurti N Das
Journal:  Eur J Clin Nutr       Date:  2022-06-14       Impact factor: 4.016

2.  CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

Authors:  Simone Weber; Victoria Kehl; Johanna Erber; Karolin I Wagner; Ana-Marija Jetzlsperger; Teresa Burrell; Kilian Schober; Philipp Schommers; Max Augustin; Claudia S Crowell; Markus Gerhard; Christof Winter; Andreas Moosmann; Christoph D Spinner; Ulrike Protzer; Dieter Hoffmann; Elvira D'Ippolito; Dirk H Busch
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

Review 3.  Immune mechanisms of hypertension.

Authors:  Grant R Drummond; Antony Vinh; Tomasz J Guzik; Christopher G Sobey
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

4.  High anti-human cytomegalovirus antibody levels are associated with the progression of essential hypertension and target organ damage in Han Chinese population.

Authors:  Zhen Li; Yan Tang; Na Tang; Qian Feng; Hua Zhong; Yong-Min Liu; La-Mei Wang; Fang He
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

5.  Human cytomegalovirus epidemiology and relationship to tuberculosis and cardiovascular disease risk factors in a rural Ugandan cohort.

Authors:  Lisa Stockdale; Stephen Nash; Angela Nalwoga; Hannah Painter; Gershim Asiki; Helen Fletcher; Robert Newton
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

6.  Lack of Association Between Cytomegalovirus Infection and Hypertensive Disorders in Pregnancy: A Case-Control Study in Durango, Mexico.

Authors:  Cosme Alvarado-Esquivel; Ada A Sandoval-Carrillo; Fernando Vazquez-Alaniz; José M Salas-Pacheco; Jesús Hernández-Tinoco; Luis Francisco Sánchez-Anguiano; Elizabeth Irasema Antuna-Salcido
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-07-13

7.  Socioeconomic status and central adiposity as determinants of stress-related biological responses relevant to cardiovascular disease risk.

Authors:  Andrew Steptoe; Tanja-Julia Hiltl; Jennifer Beam Dowd; Mark Hamer
Journal:  Brain Behav Immun       Date:  2018-11-20       Impact factor: 7.217

8.  Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea.

Authors:  Yeonju La; Da Eun Kwon; Seul Gi Yoo; Kyoung Hwa Lee; Sang Hoon Han; Yong Goo Song
Journal:  BMC Infect Dis       Date:  2019-11-08       Impact factor: 3.090

9.  Human Cytomegalovirus Reduces Endothelin-1 Expression in Both Endothelial and Vascular Smooth Muscle Cells.

Authors:  Koon-Chu Yaiw; Abdul-Aleem Mohammad; Chato Taher; Huanhuan Leah Cui; Helena Costa; Ourania N Kostopoulou; Masany Jung; Alice Assinger; Vanessa Wilhelmi; Jiangning Yang; Klas Strååt; Afsar Rahbar; John Pernow; Cecilia Söderberg-Nauclér
Journal:  Microorganisms       Date:  2021-05-25

10.  Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang.

Authors:  Qian Feng; Jing Hui; Na Tang; Yong-Min Liu; Hua Zhong; Zhen Li; La-Mei Wang; Yuan-Yuan Qu; Feng-Mei Deng; Fang He
Journal:  Biosci Rep       Date:  2018-06-27       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.